Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.

The skin has a complex immune system that is essential for protection and healing, requiring more research for better wound treatment.

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Niosomes are a promising, stable, and cost-effective drug delivery system with potential for improved targeting and safety.

The immune system plays a key role in tissue repair, affecting both healing quality and regenerative ability.

Melatonin in the skin helps protect against damage from stress and UV rays, and could be used to treat certain skin conditions.

Human skin can make serotonin and melatonin.

Melanocyte stem cells in hair follicles are key for hair color and could help treat greying and pigment disorders.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Stem cells are crucial for skin repair and new treatments for chronic wounds.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Melatonin is important for skin health and protection, and can be made by the skin or applied to it.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Hair color production in mice is closely linked to the hair growth phase and may also influence hair growth itself.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

The document concludes that developing generic topical drugs requires ensuring they match the original in quality, composition, and structure, and often involves complex testing and regulatory steps.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

The 2003 guidelines suggest that while some treatments can regrow hair in alopecia areata, none alter the disease's progression, and wigs may be the best option for extensive hair loss.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

The conclusion is that accurate diagnosis of different types of hair loss requires good teamwork between skin doctors and lab experts.

Hair follicle stem cells are key for hair and skin regeneration, can be reprogrammed, and have potential therapeutic uses, but also carry a risk of cancer.

Current treatments for alopecia show no significant long-term benefits.

Blocking JAK-STAT signaling can lead to hair growth.

Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.